Dr Leanne Robinson is Head of the Vector Borne Diseases and Tropical Public Health Group in the Disease Elimination Program at the Burnet Institute. Her research focuses on defining key factors that sustain residual malaria transmission and developing new surveillance and intervention strategies to strengthen control and expedite elimination. The nature of her work is highly collaborative and inter-disciplinary, with strong links to endemic country partners and control programs. Leanne has spent the past 10 years living and working in Papua New Guinea and has ongoing appointments with the Papua New Guinea Institute of Medical Research and the Walter and Eliza Hall Institute of Medical Research.Related Projects
- Access and adherence to malaria interventions
- An external quality assurance program for PCR assays to quantify parasitaemia across laboratories in the Asia-Pacific region
- Developing serological markers of recent exposure to malaria
- Epidemiological modelling for malaria elimination
- Geographical information systems and spatial decision support systems.
- Identifying “hot spots” and “hot pops” with serological surveillance and operational research of high sensitivity tests
- Identifying populations at risk of multidrug resistant malaria
- Molecular surveillance of malaria parasites to inform on local intervention strategies
- Operational research on access and coverage of malaria interventions
- Pregnant women and malaria surveillance
Related Publications
- Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region
- Asia-Pacific International Center of Excellence in Malaria Research: Maximizing Impact on Malaria Control Policy and Public Health in Cambodia and Papua New Guinea
- Assessment of IgG3 as a serological exposure marker for Plasmodium vivax in areas with moderate-high malaria transmission intensity
- Blood-Stage Parasitaemia and Age Determine Plasmodium falciparum and P. vivax Gametocytaemia in Papua New Guinea
- Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial
- Microscopic and submicroscopic Plasmodium falciparum infection, maternal anaemia and adverse pregnancy outcomes in Papua New Guinea: a cohort study
- Monitoring Plasmodium falciparum and Plasmodium vivax using microsatellite markers indicates limited changes in population structure after substantial transmission decline in Papua New Guinea
- Population heterogeneity in Plasmodium vivax relapse risk
- Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model
- Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model
- Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial
- Surveillance of molecular markers of Plasmodium falciparum artemisinin resistance (kelch13 mutations) in Papua New Guinea between 2016 and 2018
- Sustained Malaria Control Over an 8-Year Period in Papua New Guinea: The Challenge of Low-Density Asymptomatic Plasmodium Infections
- The complex relationship of exposure to new Plasmodium infections and clinical incidence in PNG
- The spatial signature of Plasmodium vivax and Plasmodium falciparum infections: quantifying the clustering of infections in cross-sectional surveys and cohort studies
- Ultra-Sensitive Detection of Plasmodium falciparumby Amplification of Multi-Copy Subtelomeric Targets
- Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment